Seamus Fernandez Analyst PerformanceSenior Managing Director and Equity Research Analyst at GuggenheimSeamus Fernandez is a stock analyst at Guggenheim focused in the medical sector, covering 27 publicly traded companies. Over the past year, Seamus Fernandez has issued 47 stock ratings, including strong buy, buy, and hold recommendations. While full access to Seamus Fernandez's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Seamus Fernandez's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings107 Last 11 YearsBuy Recommendations82.08% 87 Buy RatingsCompanies Covered27 Unique Companies Ratings Distribution106RatingsDistribution of strong buy, buy, hold, and sell ratings by Seamus Fernandez.RatingPercentageCount Strong Buy0.9%1 ratings Buy81.1%86 ratings Hold17.9%19 ratings Sell0.0%0 ratingsOut of 106 total stock ratings issued by Seamus Fernandez at Guggenheim, the majority (81.1%) have been Buy recommendations, followed by 17.9% Hold and 0.9% Strong Buy.Best & Worst CallsBest Call0000.0%MLYSFeb 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%ZLABJul 2020Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ81.5% of companies on NASDAQ22 companiesNYSE18.5% of companies on NYSE5 companiesSeamus Fernandez, an analyst at Guggenheim, currently covers 27 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical24 companies88.9%Manufacturing3 companies11.1%Seamus Fernandez of Guggenheim specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE15 companies55.6%MED - DRUGS4 companies14.8%LARGE CAP PHARMA4 companies14.8%Miscellaneous2 companies7.4%PHARMACEUTICAL PREPARATIONS1 company3.7%BIOTECHNOLOGY1 company3.7% About Seamus FernandezMr. Fernandez is a Senior Managing Director and Equity Research Analyst covering the Global Biopharmaceutical and Biotechnology sectors. Mr. Fernandez has more than 20 years of experience in the healthcare industry. Prior to joining Guggenheim, he was at LEERINK Partners, where he was a Managing Director and Senior Equity Research Analyst covering Pharmaceutical and Biotechnology companies. Previously, he was a Vice President at Cowen & Company. Mr. Fernandez earned his B.A. in Chemistry from Williams College in 1995.Follow on LinkedIn Seamus Fernandez's Ratings History at Guggenheim Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsACRSAclaris Therapeutics5/5/2026Initiated Coverage$4.53$12.00Buy$0.0000.00% ROILLYEli Lilly and Company5/5/2026Reiterated Rating$967.49$1,183.00Buy$0.0000.00% ROIACRSAclaris Therapeutics5/4/2026Upgrade$4.75Strong-Buy$0.0000.00% ROISGMTSagimet Biosciences4/29/2026Lower Price Target$8.52$25.00Buy$0.0000.00% ROILLYEli Lilly and Company4/21/2026Boost Price Target$907.66$1,183.00Buy$0.0000.00% ROIBMYBristol Myers Squibb4/8/2026Reiterated Rating$57.68$72.00Buy$0.0000.00% ROILLYEli Lilly and Company3/30/2026Lower Price Target$894.78$1,163.00Buy$0.0000.00% ROIGENBGenerate Biomedicines3/24/2026Initiated Coverage$12.52$30.00Buy$0.0000.00% ROIAPGEApogee Therapeutics3/24/2026Boost Price Target$79.24$160.00Buy$0.0000.00% ROIAMLXAmylyx Pharmaceuticals3/19/2026Boost Price Target$13.80$30.00Buy$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. TENXTenax Therapeutics3/16/2026Boost Price Target$13.84$34.00Buy$0.0000.00% ROIRYTMRhythm Pharmaceuticals2/27/2026Boost Price Target$98.07$143.00Buy$0.0000.00% ROIARQTArcutis Biotherapeutics2/27/2026Boost Price Target$27.59$35.00Buy$0.0000.00% ROILLYEli Lilly and Company2/26/2026Boost Price Target$1,012.89$1,168.00Buy$0.0000.00% ROIBMYBristol Myers Squibb2/6/2026Reiterated Rating$59.43$72.00Buy$0.0000.00% ROISGMTSagimet Biosciences2/3/2026Initiated Coverage$6.23$27.00Buy$0.0000.00% ROIPCVXVaxcyte2/2/2026Reiterated Rating$55.10$116.00Buy$0.0000.00% ROIGPCRStructure Therapeutics1/20/2026Boost Price Target$88.64$140.00Buy$0.0000.00% ROILLYEli Lilly and Company1/20/2026Lower Price Target$1,035.53$1,161.00Buy$0.0000.00% ROIMBXMBX Biosciences1/16/2026Boost Price Target$40.91$88.00Buy$0.0000.00% ROIBMYBristol Myers Squibb12/23/2025Reiterated Rating$54.68Buy$0.0000.00% ROITENXTenax Therapeutics12/17/2025Reiterated Rating$11.16$25.00Buy$0.0000.00% ROIRYTMRhythm Pharmaceuticals12/17/2025Boost Price Target$112.45$140.00Buy$0.0000.00% ROISNYSanofi12/9/2025Downgrade$48.44Neutral$0.0000.00% ROILLYEli Lilly and Company12/3/2025Reiterated Rating$1,045.50$1,163.00Buy$0.0000.00% ROICDTXCidara Therapeutics11/18/2025Downgrade$217.91Hold$0.0000.00% ROIIVAInventiva11/18/2025Lower Price Target$4.04$11.00Buy$0.0000.00% ROIMBXMBX Biosciences11/10/2025Lower Price Target$24.32$77.00Buy$0.0000.00% ROIARCTArcturus Therapeutics10/22/2025Downgrade$23.16Neutral$0.0000.00% ROILLYEli Lilly and Company10/16/2025Reiterated Rating$826.20$948.00Buy$0.0000.00% ROILLYEli Lilly and Company10/8/2025Boost Price Target$844.30$948.00Buy$0.0000.00% ROICDTXCidara Therapeutics9/24/2025Set Price Target$90.44$167.00Buy$0.0000.00% ROIAMLXAmylyx Pharmaceuticals9/15/2025Boost Price Target$11.65$25.00Buy$0.0000.00% ROITENXTenax Therapeutics8/14/2025Lower Price Target$5.84$14.00Buy$0.0000.00% ROILLYEli Lilly and Company8/13/2025Lower Price Target$647.26$875.00Buy$0.0000.00% ROICDTXCidara Therapeutics8/8/2025Reiterated Rating$62.00Buy$0.0000.00% ROIGPCRStructure Therapeutics8/7/2025Lower Price Target$16.18$90.00Buy$0.0000.00% ROIRYTMRhythm Pharmaceuticals8/6/2025Boost Price Target$89.85$120.00Buy$0.0000.00% ROILLYEli Lilly and Company7/11/2025Boost Price Target$790.23$942.00Buy$0.0000.00% ROICDTXCidara Therapeutics7/9/2025Set Price Target$49.41$69.00$0.0000.00% ROIIs this AI lab Elon’s SpaceX lifeline? (Ad)Elon Musk went from calling one AI lab 'evil' to striking a deal giving it access to SpaceX's entire Colossus 1 supercomputer - all in three months. The lab saw 80x revenue and usage growth in Q1 2026 alone, when it had only planned for 10x. 60-year Wall Street veteran Marc Chaikin calls it the most important potential IPO of 2026 - and says he's found a pre-IPO backdoor trading under $40 per share. His stock-rating system previously turned bullish on Nvidia in 2014 before a nearly 50,000% run, and on Vertiv before a 3,985% surge.Get the name and ticker symbol for free before June 16APGEApogee Therapeutics7/2/2025Reiterated Rating$44.26$116.00Buy$0.0000.00% ROIAMLXAmylyx Pharmaceuticals6/24/2025Initiated Coverage$5.02$17.00Buy$0.0000.00% ROICDTXCidara Therapeutics6/24/2025Set Price Target$44.95$68.00Buy$0.0000.00% ROILLYEli Lilly and Company6/20/2025Reiterated Rating$757.47$936.00Buy$0.0000.00% ROICDTXCidara Therapeutics5/16/2025Boost Price Target$24.01$50.00Buy$0.0000.00% ROITENXTenax Therapeutics5/15/2025Reiterated Rating$5.89$15.00Buy$0.0000.00% ROIMLYSMineralys Therapeutics5/14/2025Set Price Target$15.35$48.00Buy$0.0000.00% ROILLYEli Lilly and Company4/14/2025Lower Price Target$743.92$928.00Buy$000.0000.00% ROIARQTArcutis Biotherapeutics4/3/2025Reiterated Rating$15.71Buy$00.0000.00% ROIVERVVerve Therapeutics3/25/2025Reiterated Rating$5.50Buy$0.0000.00% ROIPCVXVaxcyte3/12/2025Reiterated Rating$72.86$160.00Buy$00.0000.00% ROIPCVXVaxcyte2/26/2025Reiterated Rating$82.18$160.00Buy$00.0000.00% ROIMTSRMetsera2/25/2025Initiated Coverage$29.81$56.00Buy$0.0000.00% ROIARQTArcutis Biotherapeutics2/24/2025Reiterated Rating$12.81Buy$00.0000.00% ROIMLYSMineralys Therapeutics2/24/2025Reiterated Rating$9.27Buy$00.0000.00% ROIARQTArcutis Biotherapeutics2/10/2025Reiterated Rating$11.25Buy$00.0000.00% ROIAPGEApogee Therapeutics2/10/2025Reiterated Rating$39.22Buy$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysWells Fargo & CompanyMorgan StanleyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerRaymond James FinancialStifel Nicolaus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
